HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaneko, K. Articles by Tomino, Y. Search for Related Content PubMed Articles by Kaneko, K. Articles by Tomino, Y.

PERITONEAL FIBROSIS INTERVENTION

Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan

Correspondence to: Y. Tomino, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421 Japan. yasu{at}med.juntendo.ac.jp

Peritoneal fibrosis (PF) is invariably observed in patients undergoing long-term peritoneal dialysis (PD). The condition is thought to occur in response to a variety of insults, including bioincompatible dialysates (acidic solution, high glucose, glucose degradation products, or a combination), peritonitis, uremia, and chronic inflammation. Recently, the pathophysiologic mechanisms that contribute to the fibrosing process have been intensively studied. Transforming growth factor-β has been shown to be a key mediator of PF. Loss of the mesothelial cell layer has been identified in several studies and shown to correlate with submesothelial thickening and vasculopathy. An association has also been identified between increased submesothelial thickness in the peritoneal membrane and increased solute transport, suggesting a relationship between PF and loss of ultrafiltration capacity. Thus, to maintain long-term PD and improve quality of life for patients, it is important to develop interventions for prevention and treatment of PF.

Several strategies for peritoneal fibrosis intervention have been reported, including developing biocompatible dialysate, targeting mediators responsible for inflammation and fibrosis, and reconstituting the peritoneum using mesothelial or bone marrow–derived cells. Recent experimental trials in animal models and clinical studies are presented in this review.

KEY WORDS: Peritoneal fibrosis; tranilast; intervention.

This article has been cited by other articles:

				X. Wang, J. Nie, Z. Jia, M. Feng, Z. Zheng, W. Chen, X. Li, W. Peng, S. Zhang, L. Sun, et al. Impaired TGF-{beta} signalling enhances peritoneal inflammation induced by E. Coli in rats Nephrol. Dial. Transplant., February 1, 2010; 25(2): 399 - 412. [Abstract] [Full Text] [PDF]

Copyright © 2007 by Multimed Inc.